MGX
NASDAQ
$1.22
Metagenomi Inc (MGX)
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.67 (+528.69%)
Market Cap
$49M
P/B Ratio
0.36
Beta (5Y)
0.97
Price Chart
Valuation
Market Cap$49M
P/S2.23
P/B0.36
Profitability
Total Revenue (TTM)$22M
Gross Profit (TTM)-$72M
EBITDA-$88M
Operating Margin-1970%
EPS-$2.28
Growth & Risk
Beta (5Y)0.97
Sharpe Ratio-0.54